{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:04:38Z","timestamp":1782939878295,"version":"3.54.5"},"reference-count":43,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Russian Science Foundation (RSF)","award":["25-25-20201"],"award-info":[{"award-number":["25-25-20201"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple myeloma (MM) is a complex genetic disease characterized by the heterogeneity of tumor cells. We have measured KRAS, NRAS, and BRAF gene mutations in circulating free tumor DNA (ctDNA) from plasma, bone marrow, and plasmacytoma samples as well as their correlation with various clinical and laboratory parameters. The prospective study included 113 MM patients (74 with plasmacytoma and 39 without), treated at the National Medical Research Center for Hematology (Moscow, Russia) from 2009 to 2024. FISH was performed on CD138+ bone marrow cells for 104 patients and array-CGH for two extramedullary plasmacytoma samples. Mutation analysis on CD138+ bone marrow cells was performed for 99 patients, on ctDNA for 80 patients, and, in 26 cases, samples of plasmacytoma were also investigated. Mutations in the KRAS, NRAS, and BRAF genes either in bone marrow, ctDNA, or plasmacytoma samples were found in 50% of patients. In patients with plasmacytoma, mutations in ctDNA were found in 28% of cases versus 0% in cases without plasmacytoma (p = 0.0007). Rare \u201cnoncanonical\u201d KRAS and NRAS gene mutations were also more frequent in ctDNA compared to the bone marrow substrate (50% versus 9%, p = 0.01). Liquid biopsy in MM, particularly identification of the KRAS, NRAS, and BRAF gene mutations in ctDNA, is a valuable instrument for prognostication. Researching the intricate mechanisms underlying extramedullary involvement, and identifying novel high-risk factors associated with the disease, is worthwhile.<\/jats:p>","DOI":"10.3390\/ijms26178505","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:02:57Z","timestamp":1756825377000},"page":"8505","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Liquid Biopsy as a Means of Assessing Prognosis and Identifying Novel Risk Factors in Multiple Myeloma"],"prefix":"10.3390","volume":"26","author":[{"given":"Maiia","family":"Soloveva","sequence":"first","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-6202","authenticated-orcid":false,"given":"Maksim","family":"Solovev","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Yakutik","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-3334","authenticated-orcid":false,"given":"Bella","family":"Biderman","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nikulina","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2957-1619","authenticated-orcid":false,"given":"Natalya","family":"Risinskaya","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Obukhova","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3337-2487","authenticated-orcid":false,"given":"Maria","family":"Gladysheva","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1082-8659","authenticated-orcid":false,"given":"Alla","family":"Kovrigina","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-598X","authenticated-orcid":false,"given":"Yulia","family":"Chabaeva","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Kulikov","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-9187","authenticated-orcid":false,"given":"Andrey","family":"Sudarikov","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Mendeleeva","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: Definition, disease assessment and treatment considerations","volume":"194","author":"Beksac","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11899-020-00568-3","article-title":"Extramedullary Disease in Multiple Myeloma","volume":"15","author":"Jagosky","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.13383","article-title":"Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation","volume":"169","author":"Weinstock","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.2002.03258.x","article-title":"Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma","volume":"116","author":"Dahl","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Firsova, M.V., Mendeleeva, L.P., Kovrigina, A.M., Solovev, M.V., and Savchenko, V.G. (2020). Plasmacytoma in patients with multiple myeloma: Morphology and immunohistochemistry. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06870-w"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.2147\/OTT.S205922","article-title":"Progress in the identification of gene mutations involved in multiple myeloma","volume":"12","author":"Hu","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy","volume":"123","author":"Mulligan","year":"2014","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2015.1046863","article-title":"Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: A single center perspective","volume":"57","author":"Gebauer","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/leu.2017.197","article-title":"Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma","volume":"32","author":"Perumal","year":"2018","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hon.3208","article-title":"Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma","volume":"41","author":"Perroud","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20004","DOI":"10.1073\/pnas.2005052117","article-title":"Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma","volume":"117","author":"Shirazi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1038\/s41467-022-33142-x","article-title":"Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma","volume":"13","author":"Yang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pasca, S., Tomuleasa, C., Teodorescu, P., Ghiaur, G., Dima, D., Moisoiu, V., Berce, C., Stefan, C., Ciechanover, A., and Einsele, H. (2019). KRAS\/NRAS\/BRAF Mutations as Potential Targets in Multiple Myeloma. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01137"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Allegra, A., Cancemi, G., Mirabile, G., Tonacci, A., Musolino, C., and Gangemi, S. (2022). Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma. Cancers, 14.","DOI":"10.3390\/cancers14174136"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-020-01897-9","article-title":"Liquid biopsies for multiple myeloma in a time of precision medicine","volume":"98","author":"Ferreira","year":"2020","journal-title":"J. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Heestermans, R., De Brouwer, W., Maes, K., Vande Broek, I., Vaeyens, F., Olsen, C., Caljon, B., De Becker, A., Bakkus, M., and Schots, R. (2022). Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study. Cancers, 14.","DOI":"10.3390\/cancers14194901"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18777","DOI":"10.1038\/s41598-024-69408-1","article-title":"Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients","volume":"14","author":"Pour","year":"2024","journal-title":"Sci Rep."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Soloveva, M., Solovev, M., Risinskaya, N., Nikulina, E., Yakutik, I., Biderman, B., Obukhova, T., Chabaeva, Y., Kulikov, S., and Sudarikov, A. (2024). Loss of Heterozygosity and Mutations in the RAS-ERK Pathway Genes in Tumor Cells of Various Loci in Multiple Myeloma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179426"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000529191","article-title":"Cytogenetic Abnormalities in Multiple Myeloma: Incidence, Prognostic Significance, and Geographic Heterogeneity in Indian and Western Populations","volume":"162","author":"Hande","year":"2022","journal-title":"Cytogenet. Genome Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","article-title":"CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hanamura, I. (2021). Gain\/Amplification of Chromosome Arm 1q21 in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13020256"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/bloodadvances.2020002711","article-title":"Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma","volume":"4","author":"Corchete","year":"2020","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","article-title":"Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3","volume":"118","author":"Shaughnessy","year":"2011","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.4161\/cc.8.16.9280","article-title":"FAS-associated factor 1 (FAF1): Diverse functions and implications for oncogenesis","volume":"8","author":"Menges","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1158\/1078-0432.CCR-08-0347","article-title":"Deletions of CDKN2C in multiple myeloma: Biological and clinical implications","volume":"14","author":"Leone","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.clml.2016.02.038","article-title":"Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression\/Relapse","volume":"16","author":"Mlynarcikova","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.17650\/1818-8346-2022-17-4-67-80","article-title":"Multiple myeloma with extramedullary plasmacytoma: Pathogenesis and clinical case","volume":"17","author":"Firsova","year":"2022","journal-title":"Oncohematology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Staniek, J., Lorenzetti, R., Heller, B., Janowska, I., Schneider, P., Unger, S., Warnatz, K., Seidl, M., Venhoff, N., and Thiel, J. (2019). TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00951"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jncimonographs\/lgn011","article-title":"Characterization of MYC translocations in multiple myeloma cell lines","volume":"2008","author":"Dib","year":"2008","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"a014373","DOI":"10.1101\/cshperspect.a014373","article-title":"c-MYC-induced genomic instability","volume":"4","author":"Kuzyk","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/modpathol.2011.195","article-title":"Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays","volume":"25","author":"Fontanillo","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"18173","DOI":"10.1007\/s00432-023-05505-4","article-title":"SNP array genomic analysis of matched pairs of brain and liver metastases in primary colorectal cancer","volume":"149","author":"Brandt","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3109\/10428194.2011.647311","article-title":"Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration","volume":"53","author":"Wang","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1535-6108(04)00030-3","article-title":"c-maf in multiple myeloma: An oncogene enhancing tumor-stroma interactions","volume":"5","author":"Kienast","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/sj.leu.2404669","article-title":"c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma","volume":"21","author":"Chang","year":"2007","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/gcc.21981","article-title":"Shattered and stitched chromosomes-chromothripsis and chromoanasynthesis-manifestations of a new chromosome crisis?","volume":"51","author":"Righolt","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood-2011-03-344069","article-title":"Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients","volume":"118","author":"Magrangeas","year":"2011","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8505\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:37:31Z","timestamp":1760035051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":43,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26178505"],"URL":"https:\/\/doi.org\/10.3390\/ijms26178505","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}